Navigation Links
Genetic and Proteomic Advances Pave the Way for Next-Generation Leukemia Therapies
Date:12/10/2011

aggressive leukemia that can be fatal within weeks to months of diagnosis without proper treatment. However, with the recent development of targeted therapies, additional research has focused on improving patient outcomes while reducing toxicity associated with conventional chemotherapy regimens. Monoclonal antibodies, or MABs, attach to the cancer cell surface and, when conjugated to a toxin, release the toxin into the cell. MABs are a relatively new type of targeted therapy and are considered an enhancement to chemotherapy that allows treatment to target specific cells while reducing the toxicity to healthy cells. Because GO binds to CD33, an antigen present on AML cells, but not to normal hematopoietic stem cells, it has been the focus of recent research because of its ability to be directed specifically to AML cells.

To evaluate the efficacy of GO when used with chemotherapy in older AML patients, a team of researchers with the Acute Leukemia French Association designed a Phase III, prospective, open-label, randomized trial. Primary study endpoints focused on event-free survival (EFS); secondary endpoints included response rate, disease-free survival (DFS), overall survival (OS), and safety over a three-year follow-up period. Study participants (adults age 50-70 with previously untreated de novo, or first occurrence of, AML) were randomized into one of two treatment arms – either standard chemotherapy referred to as DA, (daunorubicin, ara-C, n=134) or chemotherapy with the addition of GO (DAGO, n=137). 

The study demonstrated that adding GO to a standard chemotherapy regimen significantly improved EFS and OS in older adult AML patients. At two years of follow-up, the rate of EFS was estimated at 15.6 percent in the DA arm compared with 41.4 percent in the DAGO arm. DFS was estimated at 18.1 percent in the DA arm versus 48.5 percent in the DAGO arm. The benefit in EFS was observed in all age groups and translated into a longer OS
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Signal Genetics Announces Launch of Next Generation Genetic Multiple Myeloma Predictive Testing Product-MyPRS Plus™
2. VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
3. Abbotts Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
4. Novel New Dog DNA Test Turns Breeders Into Genetic Matchmakers
5. Genetic Profile Identified for Alzheimers Patients Showing Heightened Response to Acceras Breakthrough Product Axona®
6. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
7. American College of Medical Genetics Applauds HHS Secretarys Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease
8. Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology
9. The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
10. Genetic Testing Can Help the US Cut Costs and Improve Health Care
11. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... 30 CEL-SCI Corporation,(Amex: CVM ) announced that ... Rodman & Renshaw 9th Annual Healthcare Conference being,held at ... The presentation,will be focused on its Phase III cancer ... to become a new first line standard of,care treatment ...
... Oct. 29 As a follow up to ... eliminating,Methicillin resistant Staphylococcus aureus (MRSA), the Association for,Professionals ... days next,month in Atlanta to discuss new developments ... "MRSA: The Call to Action 1 Year ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2APIC Conference to Discuss MRSA Elimination 2
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... The 2014 Market Research Report on ... research report on COC industry. For an overview ... its definition, classification, application, industry chain structure, industry ... also presents product specification, manufacturing process, and product ... technology and applications. Analysis also covers upstream raw ...
(Date:12/24/2014)... December 24, 2014 Dental implants benefit ... a tooth replacement. They offer the strongest and most ... over other forms of tooth replacement. They will never ... the adjacent teeth for support, and they prevent the ... been told that they are not suitable candidates for ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2
... Elsevier Middle East announces that the Journal ... been selected for inclusion in MEDLINE, the premier bibliographic database ... articles indexed, the indexing terms and the abstract printed in ... Indexing using the US National Library of Medicine,s (NLM) advanced ...
... A new independent study by HealthGrades of patient outcomes ... had a 72% lower risk of dying when compared with ... held steady over the past years even as overall mortality ... performed at the level of 5-star rated hospitals over the ...
... release is available in French . ... anesthesia has been performed at the McGill University Health ... work from remote locations, was put to work this ... providing automated anesthesia since 2008. The two combined to ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... a benefit to mothers and their infants from taking supplemental ... new Australian study finds no such benefit. In ... women, the researchers found no benefit from DHA in reducing ...
... Reporter , TUESDAY, Oct. 19 (HealthDay News) -- Patients ... attacks, stroke and other problems after their operations, and ... studies find. In the aspirin study, researchers identified ... surgeries. Of those, 860 were taking aspirin in the ...
... 2010 Dogs may not only be man,s best friend, ... of children with special needs. According to a new Universit ... the anxiety and enhance the socialization skills of children with ... Psychoneuroendocrinology may be a relatively simple solution to ...
Cached Medicine News:Health News:New ratings of American hospitals released with quality study by HealthGrades 2Health News:New ratings of American hospitals released with quality study by HealthGrades 3Health News:McSleepy meets DaVinci 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 4Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 2Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 3Health News:Children's best friend 2
Pneumatic oscillating saw, 35k cpm, available with various hose connector styles....
... hand throttle. Accepts all 1000 and 2000 ... hose 9000-000, or existing hose with Microaire ... or existing hose with Linvatec/Hall connector (1000-200). ... hose with 3M connector (1000-300). , 10ft ...
Pneumatic extended oscillating saw, 35k cpm, available with various hose connector styles....
Pneumatic pencil-grip wire driver, 3000 rpm, available with various hose connector styles....
Medicine Products: